Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV

Completed · Phase 3

Conditions studied: Hepatitis C

In brief

To study the combination of Daclatasvir and Sofosbuvir for the treatment of hepatitis C virus (HCV) Genotype 3 infection

Key facts

Study ID
NCT02032901
Run by
Bristol-Myers Squibb
People needed
173
Starts
2014-01-01
Expected to finish
2014-12-01
Last updated by the study team
2015-10-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.